BRTX
BioRestorative Therapies, Inc.

Mr. Alstodt, age 47, is a senior healthcare executive with over 25 years of experience in the medical device, biopharmaceutical and healthcare services sectors. In 2013, he founded and became CEO of MedVest Consulting Corporation ("MedVest"), an advisory and capital firm that was formed to focus exclusively on the healthcare industry. Prior to Medvest, Mr. Alstodt was a career investment banker with over 20 years of experience with respect to acquisitions, leveraged buyouts, private and public financings, exclusive sales, takeover defenses, joint ventures, restructurings and general advisory services.

Francisco Silva joined BRT in April 2011. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs. From 2007 to 2011, Mr. Silva held positions with companies engaged in the commercialization of human-based biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.

Mr. Alstodt, age 47, is a senior healthcare executive with over 25 years of experience in the medical device, biopharmaceutical and healthcare services sectors. In 2013, he founded and became CEO of MedVest Consulting Corporation ("MedVest"), an advisory and capital firm that was formed to focus exclusively on the healthcare industry. Prior to Medvest, Mr. Alstodt was a career investment banker with over 20 years of experience with respect to acquisitions, leveraged buyouts, private and public financings, exclusive sales, takeover defenses, joint ventures, restructurings and general advisory services.

Francisco Silva joined BRT in April 2011. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs. From 2007 to 2011, Mr. Silva held positions with companies engaged in the commercialization of human-based biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.